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ABSTRACT The research roots of 19fluorine (19F) magnetic 
resonance imaging (MRI) date back over 35 years. Over 
that time span, 1H imaging flourished and was adopted 
worldwide with an endless array of applications and imaging 
approaches, making magnetic resonance an indispensable 
pillar of biomedical diagnostic imaging. For many years 
during this timeframe, 19F imaging research continued at a 
slow pace as the various attributes of the technique were 
explored. However, over the last decade and particularly 
the last several years, the pace and clinical relevance of 
19F imaging has exploded. In part, this is due to advances 
in MRI instrumentation, 19F/1H coil designs, and ultrafast 
pulse sequence development for both preclinical and clinical 
scanners. These achievements, coupled with interest in 
the molecular imaging of anatomy and physiology, and 
combined with a cadre of innovative agents, have brought the 
concept of 19F into early clinical evaluation. In this review, we 
attempt to provide a slice of this rich history of research and 
development, with a particular focus on liquid perﬂ uorocarbon 
compound-based agents.
KEYWORDS fluorine, magnetic resonance imaging (MRI), 
dual-tuned coil, perﬂ uorocarbon, angiogenesis, cell labeling
1 Introduction
Although hydrogen-based (1H) magnetic resonance imaging 
(MRI) predominates over the cadre of magnetic resonance 
(MR) techniques employed clinically, renewed interest in 
19ﬂ uorine (19F) MRI continues to increase, particularly for mo-
lecular imaging applications using perﬂ uorocarbons (PFCs) 
as a ﬂ uorine source. MR ﬂ uorine spectroscopy and imaging 
dates back to 1977, a time when h uman 1H MRI was in its in-
fancy [1]. Several investigators contributed to the early tech-
nical foundation of 19F imaging [2–7].
1.1 Why 19ﬂ uorine? 
Interest in 19F nuclei imaging reﬂ ects its potential as a quan-
titative MRI contrast agent. 19F has 100% natural abundance, 
a spin of 1/2, and a gyromagnetic ratio of 40.08 MHz·T–1 
(slightly lower than the 42.58 MHz·T–1 of 1H), resulting in 83% 
of the sensitivity of 1H [8, 9]. With seven outer-shell electrons, 
19F chemical shifts (CSs) are more sensitive to the local envi-
ronment than 1H with its single electron. Indeed, the spec-
troscopic signatures of 19F compounds can vary over a range 
more than 200 ppm [10, 11], offering the potential for deﬁ ni-
tive identiﬁ cation of many compounds even at lower clinical 
field strengths. Although soft body tissues, which contain 
55%–75% water, contribute a substantial mobile 1H signal, ﬂ u-
orine is essentially absent from soft tissues and is only found 
immobilized in bones or teeth, where its very short spin-spin 
relaxation time (T2) renders 19F virtually invisible to conven-
tional MR techniques. 19F MRI of high-density exogenous 
ﬂ uorine compounds accumulating at target sites offers high 
contrast-to-noise ratios (CNRs) and improved quantiﬁ cation 
potential. Furthermore, the negligible 19F background obvi-
ates the use of the serial pre-/post-contrast image compari-
sons that are requisite for differentiating superparamagnetic 
(e.g., iron oxide) or paramagnetic metal (e.g., gadolinium) 
contrast from the background in most molecular imaging 
studies.
1.2 Perﬂ uorocarbons (PFCs)
PFC nanoparticles are 98% PFC by volume, which for per-
ﬂ uorooctylbromide (PFOB, 1.98 g· mL–1, 498 Daltons) equates 
to a ﬂ uorine concentration of approximately 100 mol· L–1 [12]. 
PFC nanoparticles are distinctly different from other oil-
based emulsions by virtue of the physical-chemical prop-
erties of fluorine, the most electronegative of all elements, 
and the unique properties of C—F bonds [13]. The fluorine-
substituted hydrogen in perﬂ uorochemicals creates bulkier, 
stiffer compounds that typically adopt a helical conforma-
tion with the molecules chemically distinct but often closely 
intertwined [13]. The C—F bond is chemically and thermally 
stable and its dense electron cloud creates a barrier to en-
croachment by other chemical reagents, rendering it virtu-
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ally non-chemically reactive [13]. The resultant large surface 
area combined with the low polarizability of the ﬂ uorinated 
chains enhances hydrophobicity. Interestingly, PFCs are both 
hydrophobic and lipophobic!
The biocompatibility of liquid ﬂ uorocarbons is well docu-
mented in numerous preclinical animal studies. Even at large 
doses, most ﬂ uorocarbons are innocuous and physiologically 
inactive. No toxicity, carcinogenicity, mutagenicity, or tera-
togenicity effects have been reported for pure ﬂ uorocarbons 
within the 460–520 MW range. PFCs have tissue half-life resi-
dencies ranging from 4 days for PFOB up to 65 days for per-
ﬂ uorotripropylamine, and are not metabolized; rather, they 
are slowly reintroduced to the circulation in dissolved form 
by lipid carriers and expelled through the lungs. However, 
increased pulmonary residual volumes from expired PFC, 
which is denser than air, and reduced pulmonary compli-
ance, is noted with blood-transfusion-level dosages, particu-
larly with some early-generation PFC emulsions in rabbits, 
swine, and macaques, although not in mice, dogs, or humans 
[13–15]. Similarly, PFC nanoparticles are cleared through the 
monocyte-phagocyte system (MPS), previously referred to as 
the reticulo-endothelial system (RES). Repeated high dosages 
of PFCs by these cells can lead to the release of macrophage 
cytokines, resulting in flu-like symptoms [12]. Moreover, 
acute engorgement of the liver with PFC nanoparticles due to 
a large-volume infusion or repeated high-volume dosing can 
result in the transient physical compression of tissue with 
mild hepatocellular damage, resulting in reversible eleva-
tions in serum transaminases [16]. 
Furthermore, it must be recognized that in rodents, 
nanoparticles such as PFC nanoparticles can pass rapidly and 
directly into the biliary system, where they ﬂ ow into the small 
intestine [17, 18]. In non-rodent species, such as rabbits or hu-
mans, this rapid bioelimination is not present [19]. Thus, phar-
macokinetics, biodistribution, and the safety of PFC nanopar-
ticles will differ signiﬁ cantly between rodent and non-rodent 
species, affecting the dosages administered to compensate for 
the loss or the assessments of dose-safety margins of particles 
and their contrast or therapeutic payloads [18]. 
Early preclinical and later clinical research with PFCs in-
volved liquid breathing, recognizing the high oxygen-dis-
solving capacity of PFCs and the need to address surfactant 
deficiencies in preterm babies [20–25]. Although it was an 
interesting and effective application, this use of PFCs was rap-
idly superseded by the development of alternative surfactant 
replacement technologies. However, the oxygen-dissolving 
capacity of PFC emulsions was not forgotten, and efforts to 
develop these agents as artiﬁ cial blood substitutes were pur-
sued with limited success.
Fluosol-DA (Green Cross, Japan) was the first PFC emul-
sion approved for blood replacement, but it was associated 
with signiﬁ cant hemodynamic compromise related mostly to 
the choice of surfactant [26–32]. A similar particle, Fluosol-43, 
was later developed, substituting an albumin surfactant to 
counter the unstable hemodynamic issues. Fluosol-DA was 
composed of a mixture of perﬂ uorodecalin (PFD) and perﬂ u-
orotributylamine, which are ﬂ uorine compounds with com-
plicated MR spectra. From an MR cell-tracking perspective, 
PFD offers limited imaging or spectroscopy potential, even 
with today’s more highly reﬁ ned instruments and techniques 
[33, 34]. The next generation of PFCs pursued clinically for 
artiﬁ cial blood substitutes were PFOB (Alliance Pharmaceu-
ticals) and perfluorodichloro-octane (PFDCO, HemaGen/
PFC, Inc.). These ﬂ uoro-compounds reduced pulmonary gas 
stacking and decreased the time for PFC bioelimination from 
tissues. These second-generation PFC-based blood substitutes 
utilized phospholipid surfactants for better biocompatibility, 
better oxygen-dissolving capacity, and fewer signiﬁ cant side 
effects, improved bioelimination rates, and were amenable 
to large-scale commercial production. The oxygen dissolved 
in the PFC liquid was easily extracted by oxygen-deprived 
tissues. However, the oxygen-loading capacity of PFCs is lin-
early related to the partial pressure of oxygen in equilibrium 
with the emulsion. PFCs demonstrate a nearly flat, linear 
oxygen dissociation curve in contrast to the sigmoidal disso-
ciation curve of hemoglobin. As a result, most of the oxygen 
dissolved in the PFC is released in the high-pressure atmo-
sphere of the arteries, with little oxygen being available for 
the capillary network where the partial pressure of oxygen 
is lower and the need is greatest. PFC products essentially 
failed clinically as blood substitutes.
During this time, Dr. Robert Mattrey, working with the Al-
liance PFOB emulsion platform, conducted early studies to 
determine whether these particles offered clinical imaging 
potential with ultrasound (US), computed tomography (CT), 
and MRI [35–44]. Although much of this work centered upon 
liquid PFC nanoparticles for US and CT and required large 
volumes of materials to provide blood pool contrast, only 
the use of PFOB emulsions for gastrointestinal (GI) contrast 
(negative contrast) with 1H MRI gained traction. In this appli-
cation, PFOB particles offered signiﬁ cant imaging and proce-
dural advantages over standard barium contrast studies, but 
at a higher cost. The much lower cost of using barium for GI 
imaging won out.
2 MRI with PFC emulsions
The stability and significant prior human experience with 
PFOB offered a unique modiﬁ able nanoparticulate theranos-
tic platform technology that has been extensively exploited 
in a variety of medical applications by our laboratory, both 
alone and in collaboration with many others [16, 45–79]. For 
1H MRI, PFC nanoparticles provided a stable platform for 
high payloads of lipophilic gadolinium chelates to enhance 
targeted MR molecular imaging. However, with increasing 
concerns regarding gadolinium-induced nephrogenic system-
ic ﬁ brosis and acute complement activation noted in clinical 
trials [80–82], 19F imaging with targeted PFOB nanoparticles 
at 3 T was reconsidered in order to address these signiﬁ cant 
unmet clinical needs.
More recently, MR cell tracking with fluorocarbon label-
ing was pursued as an alternative to more commonly used 
iron oxide nanoparticles [83–90]. These investigators brought 
increased attention to the use of cyclic perfluoro-15-crown-
5-ether (PFCE) and linear perfluoropolyether (PFPE) mole-
cules that have repeating —CF2CF2O— units for improved 19F 
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signal-to-noise ratio (SNR) and detectability [63, 91–101]. When 
used for systemically targeted molecular imaging, the heavy 
accumulation of PFCE in the liver and spleen combined with 
its very prolonged biological clearance rate presented a note-
worthy human safety barrier to clinical translation. In the con-
text of cell tracking, the PFC emulsion particles are internal-
ized by cells ex vivo then administered, often locally by image-
guided injection, and the vast excess of PFC particles associ-
ated with systemically injected PFC emulsions is avoided. 
In this context, the prolonged duration of these compounds 
might be considered an asset for the serial cell tracking over a 
more prolonged timeframe. More recently, PFPE has gathered 
increased interest with the advent of cell tracking, with its 
> 40 chemically equivalent fluorine atoms simplifying the 
19F nuclear magnetic resonance (NMR) spectra, and a small 
T1/T2 ratio. Unusually for a PFC, the end-groups may be 
chemically functionalized, such as with dyes [92, 102]. 
3 19F detectability with MR
Since the concentrations of PFCs employed in biological sys-
tems are low, the typical 19F imaging SNR is low compared with 
that of 1H MRI. While some applications do administer large 
volumes of highly ﬂ uorinated ﬂ uoro-compounds and produce 
effective 19F images, high doses (more than 1–5 g/kg for PFCs) 
may be limited in humans by the aforementioned safety con-
cerns [12]. To date, magnetic resonance spectroscopy (MRS) 
studies in a whole-body scanner suggest a minimum detectable 
limit of 19F at 1.5 T of about 30 µmol.g–1 wet weight in a volume 
of about 33 mL in 6 min, based on surface coil measurements 
following the infusion of 5-fluorouracil (5-FU) chemotherapy 
[103]. At higher ﬁ eld strengths, spectroscopic 5-FU quantiﬁ ca-
tion of about 5 nmol.g–1 in 0.5–1.2 g samples at 11.7 T and one-
hour data acquisition is possible [104]. 
PFCE contains 20 resonant equivalent 19F nuclei that en-
rich the signal to allow 30 µmol· g–1 wet weight detection in 
a 4-min scan time in a volume of 60 µL in vivo at 9.4 T [67]. 
Related measurements by Partlow et al. [63] suggested a de-
tection limit (SNR > 3) of approximately 2000 cells for PFCE, 
approximately 10 000 cells for PFOB-labeled cells for in vitro 
with 19F MRS (11.7 T), and approximately 6000 PFCE-labeled 
cells/voxel in vitro with 19F MRI (11.7 T). For imaging at 1.5 T, 
the in situ localized injection of 4 million CE-labeled stem 
cells produced a strong ﬂ uorine signal. Quantiﬁ cation of PFC 
intracellular content following 12-hour cellular co-incubation 
without adjunctive transfection agents reached up to 3 pmol 
per cell. Moreover, the r1 contrast sensitivity of PFCE, like 
that of other PFCs, improves with increasing magnetic ﬁ eld 
strength, which has proved advantageous, as clinical MR 
instrumentation has increased from 3 T to 7 T and above. 
However, it also means that non- or off-target 19F noise has 
become proportionately more prominent. Clearly, PFC par-
ticles markedly enhance the local fluorine concentration to 
permit cell tracking or targeted molecular imaging studies.
Further 19F signal detectability at clinical ﬁ eld strengths (3 T 
and below) can be achieved by incorporating a relaxation-
modifying agent, lipid-anchored-gadolinium (Gd3+), into the 
outer surfactant layer surrounding PFC nanoparticles. Neu-
bauer et al. [105] showed that the addition of lanthanide 
imparted a four-fold augmentation of the 19F signal from 
200 nm PFC nanoparticles at 1.5 T. This was reflected as a 
125% increase in contrast signal when the nanoparticles were 
targeted to ﬁ brin clots in vitro. These investigators also noted 
that modiﬁ cations of the Gd3+ surface concentration and the 
lanthanide metal position relative to the particle surface 
could be used to tailor or eliminate the 19F beneﬁ t. This con-
cept was corroborated by Harvey et al. [106], and then further 
explored by de Vries et al. [107]. de Vries et al. studied this 
concept using three different PFC emulsions at ﬁ ve magnetic 
ﬁ eld strengths. Using PFCE and three lipophilic chelates (Gd3+ 
DOTA–DSPE, Gd3+ DOTA–C6–DSPE, and Gd3+ DTPA–BSA), 
they noted that Gd3+ DTPA–BSA, which positions the lantha-
nide metal close to the PFC core, had a strong inﬂ uence on 19F 
R1 compared with Gd3+ DOTA–DSPE and Gd3+ DOTA–C6–
DSPE, which position the metal further into the surrounding 
water and away from the PFC core. At typical clinical field 
strengths (1.5–3.0 T), Gd3+ DTPA–BSA inclusion favorably 
influenced 19F R1, but at higher field strengths (6.3–14 T), 
supplemental Gd3+ did not lead to an improvement and could 
adversely increase 19F R2. Because 19F r1 relaxivity inherently 
improves with increasing ﬁ eld strengths, as used in preclini-
cal animal scanners, the need to further augment the 19F sig-
nal with a lanthanide has diminished.
4 MR 19F coils
MRI of ﬂ uorinated contrast agents is challenged by low sen-
sitivity, especially at clinical ﬁ eld strengths (3 T or below). 19F 
molecular imaging has been enabled by the effective concen-
tration of PFC probes to speciﬁ c pathological sites via ligand-
directed homing; the image-guided local injection of cells 
enriched with high PFC payloads into regions of interest; 
the use of single resonance 19F molecules; and the correction 
of CS artifacts [108], ultrafast MR [109–111], and compressed 
sensing [100] acquisition techniques for multispectral agents. 
However, clear improvements in radiofrequency (RF) coil de-
sign, and particularly the development of dual 19F/1H imag-
ing, have emerged as essential advancements to 19F imaging 
technology [73, 112–118]. 
Single-frequency-mode RF coils for 19F/1H MRI are typical-
ly employed where the coil frequency is tuned to either 19F or 
1H frequency to maximize the SNR. This approach requires 
time and potentially leads to coil motion and displacement 
that can complicate later 19F/1H image co-registration. Two-
coil approaches such as a volume coil for 1H imaging and a 
surface coil for 19F imaging can be effective for acquiring the 
individual signals, but their inherently different sensitivity 
patterns can lead to image discordance when the two fre-
quency datasets are combined. Auto-tuned RF coils that use 
an external computer program emerged to switch resonant 
frequency are an option in some of the more expensive imag-
ing systems, but these come with increased complexity [119]. 
Overall, single-frequency-mode RF coils for 19F/1H MRI imag-
ing are challenged to overcome several issues: diminished 
SNR, differential B1 field inhomogeneity artifacts, and co-
registration error of 1H/19F signals.
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To address these challenges, dual 19F/1H coils were expl-
ored. Dual-frequency coils for two well-separated resonant 
frequencies such as 1H (42.58 MHz·T–1) and 13C (10.71 MHz·T–1) 
are typically designed utilizing shunting and multiple pole 
methods. Unfortunately, this classic approach is less suited 
for 19F/1H MRI coils where the 19F gyromagnetic ratio of 
40.08 MHz·T–1 is close to that of 1H. One design approach 
considered a universal matching circuit via multiport input 
for multi-frequency. Another tactic considered close dual-
frequency coil strategies based on the special resonant prop-
erty of a birdcage resonator, particularly for preclinical scan-
ners, wherein two crossed cages or two different modes of a 
birdcage are used to achieve the double resonance.
A more progressive approach was proposed by Hockett et 
al. [118], who employed a tuned and matched dual-frequency 
coil that used an enclosed solenoid geometry reported by re-
searchers at Philips Research [120], but that was modiﬁ ed to 
meet the operational constraints imposed by the size and ac-
cess requirements of an arthritic rabbit-knee model (Figures 1 
and 2). This design extended the dual-frequency coil simulta-
neous image concept to include a double-tuned circuit with 
an input parallel resistor, inductor, and capacitor (RLC) auxil-
iary resonant circuit in series with an open-coil design based 
on a geometry proposed by Ballon et al. [121] and Jin et al. 
[122]. The open-coil design allowed a cylindrical shape and 
multiple loops, with current steering similar to a birdcage de-
sign, in order to provide a larger coil volume with enhanced 
field uniformity while maintaining adequate sensitivity to 
support transmit-and-receive imaging of the rabbit knee at 
both nuclei at 3 T. A unique strength of this design was its 
ability to image both anatomy and exogenous contrast truly 
simultaneously, eliminating the chance for image registration 
problems while maximizing throughput. Subsequently, Hu 
et al. [117] extended the coupled resonator model approach of 
Hockett et al. [118] to a universal design technique affording 
the fabrication of 19F/1H dual-frequency coils in diverse con-
ﬁ gurations. For these approaches, the matching required for 
a dual-frequency coil to function properly with the differen-
tial impedances at the two resonant frequencies was a critical 
design challenge. Hockett et al. [118] and later Hu et al. [117] 
showed that a series capacitive matching network was theo-
retically effective in matching the coupled resonator to 50 Ω 
for both 19F and 1H frequencies. Hu et al. implemented this 
19F/1H dual-frequency birdcage RF coil for in vivo imaging at 
4.7 T to illustrate its feasibility (Figure 3). They demonstrated 
rapid acquisitions with a high SNR saddle coil using an ac-
tively decoupled surface coil on 19F frequency for both 19F and 
1H signals. They achieved homogeneous excitation with high 
sensitivity for 19F MRI, while retaining sufficient SNR from 
1H signal for anatomy images.
Figure 1. The dual-frequency coil is conceptualized as two separate L CR 
resonators (L1, C1, R1) and (L2, C2, R2) electrically coupled via capacitor C3. 
(a) The equivalent circuit diagram; (b) the impedance magnitude output of a 
SPICE simulation of two capacitively coupled resonators. 19F is 120.43 MHz and 
1H is 127.49 MHz at 3 T. Reproduced with permission from Ref. [118].
Figure 2. (a) Photograph of completed dual-frequency coil and supporting 
electronics. The six-leg (ﬁ ve-loop) coil structure is shown in the upper left portion 
of the image. (b) High-resolution 1H image of an arthritic rabbit knee, highlighting 
anatomic features. (c) Spectral lines corresponding to the measured fluorine 
resonance from PFCE emulsion and triﬂ uoracetic acid (TFA) reference standard. 
Simultaneously acquired (d) 1H and (e) 19F images of the rabbit knee post 
injection of the PFCE emulsion. Reproduced with permission from Ref. [118].
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Recently, 19F/1H dual-tuned coils were extended by Ji et al. in Niendorf’s lab for 
human application at 7.0 T [116]. A modular eight-channel 19F/1H transceiver RF 
coil array for the human knee was designed and tested that enabled 19F localization 
of an epicutaneously applied 19F-NSAID ointment. In-plane spatial resolution was 
very high (1.5 mm × 1.5 mm) and acquisition was rapid—about three minutes of 
scan time. This eight-channel high-sensitivity array was adaptably positioned close 
to the patient and allowed for transmit ﬁ eld (B1+) s haping by adjusting the magni-
tude and phase of different channels to minimize inhomogeneity at this ultrahigh 
frequency.
5 MR 19F PFC imaging
While high specificity for 19F detection comes from the virtual absence of back-
ground 19F in the body, this same paucity of signal complicates image formation 
optimization and motion assessments. A typical MR scanner automatically per-
forms operator-independent preparation steps to determine the appropriate power 
setting for a desired ﬂ ip angle, RF coil, and patient combination. Such power op-
timization requires rapid detection of a robust signal. The low SNR of 19F images 
precludes this essential power optimization step for single 19F nuclei coils.
For better simultaneous 19F/1H MRI on a clinical 3 T scanner, Keupp et al. [114] 
devised a novel architecture with modiﬁ ed spectrometers and software for concur-
rent dual-nuclei MRI, while other components of the scanner (e.g., the gradient sys-
tem and magnet) remained unchanged. Separate transmitter and receiver devices 
for the non-proton nucleus were added in order to achieve simultaneous excitation 
of 1H and 19F nuclei. Waveforms for the prescribed RF pulses were created inde-
pendently for each nucleus and fed simultaneously into the RF ampliﬁ er. With this 
instrumentation in particular, power optimization of the 19F/1H dual-tuned coils 
for a speciﬁ c patient can be performed by using the rich 1H signal and then apply-
ing the results for both 1H and 19F imaging [123]. The spatial inhomogeneity of RF 
coil sensitivity (which is present in all MRI coils, and is often corrected “behind the 
scenes” in clinical scanners) can be ap-
plied from the 1H to the 19F channel in 
these dual-tuned coils [73]. For absolute 
quantitation of the 19F signal, as for se-
rial clinical molecular imaging, these 
calibration and correction steps will be 
required.
The scan times for 1H scans can be 
quite low due to the abundance of tis-
sue water, whereas the paucity of the 
19F signal must be compensated with 
extended signal averaging. This makes 
the acquisition prone to motion artifacts 
arising from anatomical and patient 
motion movement, which lead to signal 
degradation due to blurring and 19F/1H 
image misregistration. Simultaneous 
readout of both 1H and 19F affords mo-
tion artifact correction using the 1H 
image data that is then applied to the 
19F images [114]. With 3D radial k-space 
ﬁ lling, under-sampling 1H images (i.e., 
reconstructed at a much higher tempo-
ral resolution than the full 19F k- space) 
allow data motion correction over pro-
longed image-acquisition times, which 
increases 19F SNR and quantification 
accuracy [114]. 
Fluorine detection is technically chal-
lenged by compounds with short T2 
relaxation times varying across their 
spectral peaks and CS artifacts. To ad-
dress these issues with multinuclear 
MR, Mastropietro et al. [124] optimized 
the sequence parameters of fast spin 
echo (FSE/RARE). Although the ap-
proach was effective for some 19F mol-
ecules, compounds with unique spectral 
properties required individual param-
eter tuning to the local environment. 
For multispectral compounds such as 
PFOB, common 19F resonant groups 
can be selected for acquisition at the ex-
pense of the diminished SNR efﬁ ciency 
incurred by ignoring other spectral 
lines of the compound. To capture full 
spectral information, a technique of 
chemical species separation by iterative 
decomposition with echo asymmetry 
and least-squares estimation (IDEAL) 
was studied, but this technique neces-
sitates complex δB0 correction [125, 126]. 
To capture signal from all PFOB spins, 
echo time (TE) encoding with relaxation 
correction has been implemented [127] 
in addition to pulse-phase encod-
ing (PPE) [128]. Interestingly, chem-
ical-shi f t-independent techniques 
Figure 3. (a) Circuit design of a 19F/1H dual-frequency actively decoupled transmit-only saddle coil for a 
mouse image at 4.7 T. (b) S11 of actively decoupled dual-frequency saddle coil when switched on and off. 
(c, d) Norma lized B1 ﬁ eld along the diameter and axis of the actively decoupled dual-frequency saddle coil 
when switched on and off. Reproduced with permission from Ref. [117].
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Figure 4. A simultaneous 3D 19F/1H UTE-SSFP pulse sequence. It consists 
of simultaneous 19F/1H RF excitation and subsequent FID acquisition at an 
ultra-short echo time, using balanced gradients (m, mr) with a Wong-type radial 
readout trajectory. Reproduced with permission from Ref. [111].
like fluorine ultrafast turbo spectroscopic imaging (F-
uTSI) were developed and shown to capture the entire 
19F spectrum, albeit with a significant acquisition time 
penalty [129].
A more straightforward method to image complex 19F spin 
systems, in consideration of destructive phase interference, 
is to acquire the signal before the spins de-phase, as in ultra-
s hort echo time (UTE) imaging [130]. UTE potentially boosts 
19F SNR by capturing an NMR signal before line de-phasing 
and significant transverse relaxation can occur [109]. Bal-
anced steady-state free precession (SSFP) is a technique in 
which each gradient pulse within one repetition time (TR) is 
compensated by a gradient pulse with an opposite polarity, 
resulting in a single, re-phased magnetization vector [131]. As 
such, the SSFP sequence retains much of the initial magneti-
zation (M0), which yields a steady-state MR signal with high 
achievable SNR. Balanced SSFP sequences have been used 
effectively for imaging mesenchymal cells labeled with the 
CellSense™ 19F PFC probe, which has a single resonance peak 
[132]. To achieve highly sensitive detection of multi-resonant 
imaging labels like PFOB, a dual-frequency 19F/1H UTE-
balanced SSFP pulse sequence with 3D radial readout was 
employed on a clinical 3 T scanner to image PFC (Figure 4) 
[111]. The majority of the PFOB ﬂ uorine nuclei (12 of 17) are 
located in the CF2 resonances within a 1 kHz CS range that 
can be captured within a 90 µs TE of the UTE-SSFP sequence. 
This short TE preserves the NMR signal from signiﬁ cant de-
phasing and avoids the destructive superposition of these 
resonances. The SNR gain achieved by constructive addition 
of the CF2 lines more than compensates for the loss in SNR 
efﬁ ciency imposed by 3D radial sampling (25%) and the free 
induction decay (FID) readout.
dual-nuclei techniques. Once the complex spectral signal 
is acquired with this sequence, the 3D radial-filled k-space 
data are directly reconstructed without post-processing, in 
contrast to CS imaging. The 3D radial dataset offers multi-
resolution reconstruction, allowing analysis of the 19F and 1H 
data at different spatial resolutions as well as the opportunity 
to motion-correct the non-proton signal with temporal sub-
sampling of the 1H data [114]. 
UTE-SSFP may not be ideal for all PFC probes, however. 
For agents with single resonance peaks, such as PFCE or 
PFPE, decreased SNR efﬁ ciency may result from the 3D radial 
k-space sampling and FID readout. Furthermore, UTE-SSFP 
requires that the particular line group selected must occur 
within a 1–2 kHz bandwidth for appropriate spatial resolu-
tion of the 3D radial readout with standard gradient systems. 
For PFOB, the 19F line group of interest spans a 1 kHz band-
width, but other probes can differ. For compounds with fewer 
19F nuclei than typically associated with PFC emulsions, par-
ticularly when imaged at higher than current clinical field 
strengths in order to achieve SNR, alternative approaches to 
UTE imaging such as zero time echo (ZTE) may be optimal 
[109]. Regardless, ultrafast imaging capability on modern MR 
instrumentation has enabled a renaissance in 19F imaging 
that was impossible a decade ago.
6 19F cell tracking and macrophage labeling
The concepts of tracking cellular fates in vivo following the 
uptake of PFC emulsions labeled ex vivo or in situ have been 
well reviewed but deserve some recapitulation, since this 
concept has progressed from the bench to the clinic within 
the last several years [93, 99]. Phagocytic uptake of systemi-
cally injected PFC nanoparticles is an inherent feature of 
their natural clearance from the body by the MPS. For in 
vivo in situ labeling, relatively large volumes of particles are 
intravenously introduced, whereby engulfment ensues by 
various subgroups of leukocytes, predominantly monocytes, 
macrophages, neutrophils, and dendritic cells (DCs). The 19F-
labeled leukocytes, often resident in the spleen, are recruited 
by cytokines into inflamed areas where their accumulation 
can be monitored noninvasively via MR. This concept of in 
situ PFC labeling of macrophages and the MPS organs was 
appreciated in the early studies detecting 19F hotspots in rat 
tumors and abscesses [133] and PFC emulsions were later de-
tected in myocardial infarcts and cancers, although the imag-
ing approaches were not exclusive to 19F MR and included US 
and CT [5, 35–37, 134–136]. Furthermore, studies irradiating 
the spleen to reduce its phagocytic function demonstrated 
decreased particle uptake and offered early evidence of the 
organ’s important MPS role in PFC particle clearance [137]. 
Subsequently, 19F MRI with in situ cell labeling has been used 
to monitor inflammation associated with autoimmune dis-
ease in experimental allergic encephalomyelitis (EAE) [67], 
human pancreatic cells [138], ischemic myocardium and the 
cerebrum [139], LPS-induced pulmonary inﬂ ammation [140], 
allograft rejection [96], neuroinﬂ ammatory peripheral nerve 
disease [141], and collagen-induced arthritis in rodents [97]. 
Moreover, these studies point to the qualitative relationship 
The UTE-SSFP technique offers several benefits for the 
multinuclear imaging of non-proton agents. When 19F con-
trast agents are bound to target tissues, they can exhibit fur-
ther reduced T2 relaxation due to decreased molecular mo-
tion [113]. The balanced SSFP approach contributes high SNR 
for imaging labels with unfavorable relaxation conditions for 
gradient-echo methods due to M0 saturation exhibiting a long 
T1 and short T2. By altering offset frequency and excitation 
bandwidth for a particular 19F line group of interest, UTE-
SSFP can be customized to the probe of choice. Furthermore, 
the UTE-SSFP sequence can be combined with simultaneous 
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between the severity of the inﬂ ammation and the magnitude 
of the 19F MRI signal. Indeed, this concept is well established, 
and is perhaps preferable in some respects to iron-oxide-
based cell-tracking techniques. Iron oxides are very sensitive 
markers of cells, but they tend to reduce soft-tissue resolution 
due to superparamagnetic bloom artifacts, which are avoided 
with 19F. The lack of magnetic artifact allows tissue and cel-
lular boundary image detail to remain.
In many reports, specific cells such as DCs [94] and stem 
cells [63] have been labeled ex vivo and then injected or im-
planted in vivo. 19F imaging has been performed acutely in 
order to demonstrate the technique and even show the poten-
tial for using different PFCs to differentiate cell types simul-
taneously as well as longitudinally to follow their migration. 
When labeling cells ex vivo, the speciﬁ c lineage and 19F cell-
labeling efﬁ ciency is known and can be used to improve the 
biological and quantitative interpretation of the resultant 
data. In contradistinction, in situ labeling allows the 19F signal 
to be qualitatively followed but precludes accurately know-
ing which cell types are being imaged or quantitatively re-
lated to the 19F signal intensity on spin-density weighted MR 
techniques.
Recently, Ahrens et al. [98] used PFPE nanoparticles (CS-
1000) for 19F cell-tracking of immunotherapeutic mature DCs 
in patients with colorectal adenocarcinoma. The PFPE agent 
used was rigorously tested for acute toxicity, cytotoxicity, and 
genotoxicity prior to clinical use without adverse effects at 
100-fold the clinical dose anticipated. PFPE was incorporated 
into nonphagocytic cells without adjunctive cationic lipids 
and without altering the cellular phenotype. It is notable that 
only viable cells were labeled with PFPE. However, in vivo 
cell death can liberate the PFC, which may then be engulfed 
by macrophages, leading to a false positive signal. The same 
is true of iron oxides, and can be an inherent confounding 
problem of the technique in general. Post-implantation DCs 
were noted as “hotspots” at the injection site, and that signal 
diminished by 50% the next day. This result afﬁ rmed that the 
label cells were injected and, in two patients, the technique 
allowed the number of cells to be estimated. The further dis-
position of the cells was not appreciated. A correlation with 
the lack of response—whether due to an inadequate thera-
peutic load injected, marked early cell death, DC migration, 
or an ineffectiveness of the treatment concept—remains an 
open question. Although this clinical study used rudimenta-
ry data-acquisition methods and a suboptimal MRI detector 
(surface coil) design, it still showed the potential for 19F imag-
ing efﬁ cacy with a clinical scanner. The advancements in coil, 
pulse sequence design, and motion correction are now better 
understood and when implemented will likely improve the 
diagnostic results achieved.
7 19F PFC nanoparticle molecular imaging of 
thrombus
The use of 19F imaging and PFC nanoparticles for thrombus 
diagnosis dates back more than a decade. Thrombus is rich in 
molecular epitopes for targeting, in particular ﬁ brin, throm-
bin, and in some instances, platelets. Yu et al. [142] demon-
strated high-ﬁ eld molecular imaging of ﬁ brin-targeted para-
magnetic PFOB nanoparticles using human clot phantoms, 
and showed not only the 1H T1-weighted contrast of PFC 
particles decorated with surface Gd3+ DTPA-BOA, but also the 
corresponding 19F signal. Although the improved 19F R1/R2 
relaxation enhancement of Gd3+ DTPA-BOA in the lipid sur-
factant was not appreciated at the time, in hindsight it is clear 
that this factor contributed to the robust 19F result.
In subsequent studies, the dual imaging proton and the 
quantitative potential of 19F imaging and spectroscopy with 
paramagnetic PFOB nanoparticles was demonstrated at 4.7 T, 
and was corroborated by proton relaxation rates at 1.5 T and 
radioactive gadolinium metal using neutron activation analy-
sis [55]. The clinical relevance of this concept was illustrated 
with ex vivo human carotid endarterectomy for uniquely and 
quantitatively detecting ruptured plaque (Figure 5). The use 
of 19F spectroscopy and imaging for the simultaneous differ-
entiation of two nanoparticle emulsions with PFCE or PFOB 
cores targeted to ﬁ brin clot phantoms illustrated the potential 
for noninvasive phenotypic characterization of pathological 
targets. The underlying proposition was that pathologic dif-
ferentiation of complex tissues will require multiple biomark-
ers, and the unique ratio of the receptor expression levels 
could be used to characterize and diagnose pathology. In 
this experiment, the PFCE nanoparticles incorporated gado-
linium. 19F images were acquired using steady-state gradient-
echo techniques and spectra acquired with volume-selective 
and nonselective sampling. The imaging used conventional 
T1-weighted imaging clots with PFCE nanoparticles, which 
were enhanced as expected with the intensity contrast sig-
nal decreasing monotonically with particle concentration. 
All clots were visualized using wide-bandwidth 19F imaging 
while a restricted bandwidth excitation permitted the inde-
pendent imaging of PFCE or PFOB nanoparticles.
In the coagulation cascade, thrombin represents a principal 
target of direct and speciﬁ c anticoagulants, which can be ac-
cessed via a thrombin inhibitor (Phe[D]-Pro -Arg-chlorometh-
ylketone, or PPACK) complexed onto colloidal nanoparticles 
[143]. This theranostic construct was devised as a first-in-
Figure 5. Proton and ﬂ uorine images of a carotid endarterectomy specimen 
obtained at 4.7 T (independently) and fused. Note that the fluorine pixels 
superimposed on the T1-weighted contrast image confirm and quantify the 
fibrin-specific signal. Also note that some regions of apparent T1 brightness 
are not aligned with the ﬂ uorine signal, and are most likely not derived from the 
paramagnetic nanoparticle. (Bright spots do not necessarily indicate a contrast 
agent.) Reproduced with permission from Ref. [55].
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class anticoagulant with a prolonged and highly localized 
therapeutic impact conferred by its multivalent thrombin-
absorbing particle surface. In an in vivo acute arterial throm-
bosis model, PPACK nanoparticles outperformed both 
heparin and uncomplexed PPACK in inhibiting thrombosis. 
19F MRS (11.7 T) confirmed that the PPACK nanoparticles 
speciﬁ cally bound to sites of acute thrombotic injury. The 19F 
MRI showed co-localization of particles within an artery. It is 
of interest that although these thrombin-inhibiting nanopar-
ticles only increased the systemic bleeding time for 10 min, 
they provided prolonged clot inhibition.
More recently, noninvasive identification of developing 
thrombi using 19F MRI and 2-antiplasmin peptide (α2AP)-
targeted PFC nanoemulsions was reported [144]. Ligand func-
tionality was achieved under mild coupling conditions using 
a sterol-based post-insertion technique. Targeted imaging of 
murine inferior vena cava thrombus using simultaneous ac-
quisition of 1H and 19F MR images at 9.4 T was achieved with 
excellent SNR and CNR. The α2AP-PFCs construct was also 
evaluated for the diagnosis of experimentally induced pul-
monary thromboembolism. α2AP-PFCs targeted the thrombus 
as clot formation progressed, but 60 min after thrombus in-
duction, no detectable 19F signal was appreciated. This result 
suggests that crosslinking of ﬁ brin by the thrombin-activated 
factor XIIIa was completed, and points to the utility of α2AP-
PFCs for differentiating thrombolytic labile versus drug-
resistant thrombus. This therapeutic approach could improve 
the risk-beneﬁ t balance for thrombolytic treatment.
The ﬂ uorine-rich core of PFC nanoparticles can also serve 
as a quantitative reference from which to normalize and 
characterize chemical exchange saturation transfer (CEST) 
agents targeted to fibrin clots or other targets [145]. CEST 
chelates have exchangeable protons (—NH, —OH, etc.) that 
resonate at a CS that is distinguishable from the bulk water 
signal. RF pre-pulses applied at the appropriate frequency 
and power can saturate the exchangeable protons that then 
transfer into the bulk water pool and reduce the equilib-
rium magnetization. PFC nanoparticles functionalized with 
paramagnetic CEST (PARACEST) chelates offer a switchable 
contrast, which is achieved by adjusting the pulse sequence 
parameters. This important feature of CEST agents obviates 
the need for pre- and post-injection images, which is com-
mon with most 1H-based molecular imaging contrast probes. 
Moreover, the newly designed PARACEST PFC nanoparticles 
produced a CNR of 10 at the clot surface, which helped to 
address the lack of contrast sensitivity of early PARACEST 
agents. In addition to lowering the effective detection limit 
by delivering very large payloads of PARACEST chelates on 
the PFC nanoparticle surface, the PFC core itself provided a 
19F signal for quantitative particle-binding estimation. The 
simultaneous availability of two unique signatures, 19F and 
PARACEST, directly indicated the voxel concentration of the 
PARACEST chelates that were bound. Moreover, when bound 
to the clot surface, the PARACEST nanoparticles produce 
more than two-fold higher PARACEST contrast than when 
free in suspension. This was suggested to be due to reduced 
nanoparticle mobility and slowed water-exchange kinetics. 
The increased bound water lifetime lowered the detection 
limit from 4.13 nmol· L–1 for nanoparticles in suspension to 
2.30 nmol· L–1 for nanoparticles bound to a target. Indeed, 
CEST and PARACEST agents have evolved from their humble 
beginnings to become important MR contrast agents [144, 
146–178]. 
8 19F angiogenesis imaging
Angiogenesis is a critical early feature of normal tissues, such 
as the endometrium, bone growth plates, and wound heal-
ing, as well as of pathologies such as rheumatoid arthritis, 
atherosclerosis, asthma, and cancers. The detection of angio-
genesis via molecular imaging of the ανβ3-integrin expressed 
by neoendothelial cells requires low nanomolar sensitivity 
per voxel for detectability. High-resolution 19F imaging of an-
giogenesis was ﬁ rst used to detect and quantify the neovas-
culature in a rabbit model of aortic valve disease with ανβ3-
PFC-nanoparticles [70]. Atherosclerotic New Zealand White 
rabbits were treated with ανβ3-targeted PFC nanoparticles 
or untargeted PFC nanoparticles. The excised aortic valve 
leaflets were thickened and inflamed. 19F MRS at 11.7 T of 
the valve leaﬂ ets from rabbits treated with ανβ3-targeted PFC 
nanoparticles had 220% more 19F signal than their counter-
parts receiving untargeted PFC nanoparticles. Furthermore, 
in a competitive inhibition treatment group, the valve leaﬂ et 
19F signal was reduced by 42%, supporting the speciﬁ city of 
the targeting. In a second cohort of atherosclerotic rabbits, 19F 
spectroscopy performed at 3 T using a clinical scanner again 
demonstrated the effectiveness of ανβ3-targeted PFC nanopar-
ticles for neovascular imaging, which was further corrobo-
rated with immunohistochemistry.
Molecular imaging of U87 glioblastoma at 7 T in mice us-
ing ανβ3-PFOB nanoparticles similarly showed concentrations 
in mice tumors to be greater than in the control, although 
nonspecific background signal originating in blood at this 
high-ﬁ eld strength persisted in this experiment [179]. These 
imaging results were corroborated by histology and by ﬂ uo-
rescence microscopy. Importantly, this was the ﬁ rst 19F imag-
ing example in brain tumor angiogenesis that was obtained 
with integrin-targeted PFC nanoparticles. This group later 
developed polymeric encapsulation of PFOB with an extend-
ed circulatory half-life, and then functionalized it with an 
Arg-Gly-Asp (RGD, an anti-integrin)  ligand in order to dem-
onstrate its use for tumor imaging with 19F as well [180, 181]. 
As mentioned earlier, angiogenesis is an important constit-
uent of inflammatory pulmonary diseases, such as asthma. 
Early neovascular expansion in the lungs in patients is very 
difficult to assess noninvasively, and particularly quantita-
tively. With the notable exception of signiﬁ cant lung tumors, 
pulmonary 1H MRI of parenchymal disease is challenging 
due to a paucity of tissue water protons, respiratory motion, 
and CS artifacts. 19F/1H MR molecular imaging with ανβ3-
targeted PFOB nanoparticles can be used to directly measure 
neovascularity. To validate the 19F/1H MRI technique in the 
lung, an established rat left pulmonary artery ligation (LPAL) 
model was employed [182]. LPAL induces the bronchial artery 
vasculature to proliferate into zones of acute inflammatory 
lung injury, notably surrounding the bronchioles and large 
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vasculature proximal to the ligature 
[182]. 
Three days after pulmonary artery 
ligation, simultaneous 19F/1H MRI at 3 T 
was performed following the injection 
of ανβ3-targeted PFC nanoparticles [183]. 
The injured rat lung and bronchi had an 
increased 19F signal with targeted PFC 
particles compared to the nontargeted 
agent (Figure 6). Almost no 19F signal 
was appreciated in the control right 
lungs with targeted or nontargeted 
PFC nanoparticles. Competitive inhibi-
tion of ανβ3-targeted PFC nanoparticles 
decreased the 19F angiogenesis signal 
in the ischemic left lung, a reduction 
that was not different from the 19F sig-
nal obtained in the nontargeted group 
(Figure 7). Supporting fluorescent and 
light microscopy illustrated the heavy 
nanoparticle decorating of vessel walls 
in and around the large bronchi and 
large pulmonary vessels. These results 
demonstrated that 19F/1H MR molecular 
imaging with ανβ3-PFC nanoparticles 
provided a direct and reproducible 
readout of neovascularization in the in-
jured lung.
Next, this validated 19F imaging tech-
nique was applied to interrogate the ab-
errant bronchial neovascularity associ-
ated with chronic asthmatic airway as a 
possible factor contributing to persistent 
airway wall edema and sustained leu-
kocyte recruitment [184]. The causal re-
lationships between exposure to house 
dust mites (HDMs) and the development of asthma is well established. Rats were 
exposed bi-weekly to HDM inhalation and studied after one, two, or three weeks 
of antigen exposure. The time course of the appearance of increased blood vessels 
within the airway wall was assessed noninvasively with 19F MRI and corroborated 
with quantitative microscopy. A methacholine challenge study was used to assess 
for hyper-reactive airway response, characteristic of asthma. After three weeks 
of HDM exposure (six inhalation doses), the number of mature vessels counted 
within the airway walls of bronchial airways (0.5–3 mm perimeter) increased sig-
niﬁ cantly. These vascular changes were accompanied by increased airway respon-
siveness to methacholine. However, after only one or two weeks of the HDM chal-
lenge, no signiﬁ cant change in functional vessel numbers or methacholine airway 
reactivity was noted. 19F/1H MRI at 3 T with ανβ3-targeted PFC nanoparticle infu-
sion established increases in 19F signal in rat airways after one and two weeks of bi-
weekly HDM, revealing the earlier activation of the process of neovascularization 
before increased airway hyper-reactivity was appreciated (Figure 8). Moreover, 
when gross pathological and clinical manifestations were manifest, 19F molecular 
imaging showed that the acute neovascular expansion phase had passed.
This use of 19F/1H for pulmonary imaging is particularly relevant because MRI is 
not clinically exploited for interrogating diffuse parenchymal lung diseases, yet the 
prevalence of these pathologies and healthcare costs to treat them are soaring. Al-
though CT is often used to study lung pathology, in general it has a low sensitivity 
to early disease, where medical management can have the greatest impact. More-
over, for patients dealing with lifetime chronic diseases, serial exposure to ionizing 
radiation is problematic, particularly for patients who are diagnosed at younger 
ages. Echocardiography to assess right ventricular (RV) function, morphology, and 
valvular hemodynamics is often used as a surrogate marker for increasing pulmo-
nary hypertension, but it is imprecise, relatively insensitive, and provides no direct 
quantiﬁ cation of the spatial extent or distribution of the disease in the lung itself. 
Indeed, simultaneous 19F/1H MR molecular imaging at 3 T with the improvements 
Figure 6. Comparison of left-right lung signal 
in day 3 LPAL rats and sham-operated rats, 
administered nontargeted, ανβ3-targeted, or 
competitive-inhibited ανβ3-targeted PFC nanop-
articles after two hours. LPAL rats receiving ανβ3-
targeted nanoparticles had the greatest 19F left lung 
signal compared to the nontargeted PFC particles 
(P = 0.005). Competitive inhibition with ανβ3-targeted 
oil nanoparticles decreased the lung 19F signal 
(P = 0.0001). The 19F signal in sham-operated 
control rats was also greatly decreased (P = 0.002). 
Reproduced with permission From Ref. [183].
Figure 7. Whole-body 19F/1H images of a rat thorax and abdomen two hours after the injection of 
ανβ3-targeted or nontargeted (NT) PFC nanoparticles (green). (a) Coronal plane of the rat following ανβ3-
targeted nanoparticles, showing accumulation in the left lung adjacent to the heart, and reticuloendothelial 
(RES) clearance of particles in the liver and spleen. Little signal was detected in the right lung. (b) Sagittal 
view of the targeted nanoparticle accumulation in the left lung. (c) Transverse view at the level of the heart, 
showing bound nanoparticles in the left but not in the right lung. (d) Coronal plane of the rat following 
NT-nanoparticles, showing no visual accumulation in the injured left lung adjacent to the heart, but with 
signiﬁ cant RES clearance of particles into the liver and spleen. (e, f) Sagittal and transverse views of the 
rat thorax following NT-nanoparticles showing negligible accumulation in the injured lung. No signal is 
appreciated in the right lung. In all these images, no off-target contrast was appreciated in the surrounding 
musculature. The 1H image shown above was obtained at higher resolution using a clinical 3 T scanner 
for higher thoracic anatomical clarity. Yellow arrows indicate examples of ringing artifact recognized in this 
particular MRI sequence, which are common to high-signal areas (i.e., liver and spleen). Reproduced with 
permission from Ref. [183].
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in coils and imaging techniques now offers high potential to 
address these inﬂ ammation-based typically ﬁ brotic diseases 
when the cadre of new medicants can be useful and opti-
mized to the individual.
9 Conclusions
This introduction to 19F MRI has illustrated how a concept 
first considered in the 1970s is now on the verge of clinical 
relevance in 2015. Improvements in MR instrumentation, 
coils, and pulse sequences have begun to overcome the fun-
damental issues that have precluded clinical translation for 
many years. Whether for cell or targeted molecular imaging 
or for other applications such as oxygen sensing [185–190], 
PFC particles are coming to the fore in MR by virtue of their 
dense fluorine content and relatively bio-inert properties, 
offering imaging possibilities that take advantage of and 
complement traditional 1H MRI. While more work needs to 
be done, it seems that a breakthrough application is near, and 
once that is achieved, the ﬂ oodgates of applications for these 
unique nuclei will be open. The only barrier that seems to 
stand between this technology and its clinical reality is un-
mitigated will power.
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